La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

In his resignation letter, Marks cited disagreement with HHS Secretary Robert F. Kennedy Jr., who he said pushed ...

The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death ...

Reduction-in-force notices went out Tuesday morning to employees across HHS. At FDA, OND director Peter Stein is departing as ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Many HHS department heads and staff were unaware of plans to fire some 10,000 employees until they were publicly disclosed ...

The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical ...

Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create ...

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.